Work

Association of HLA ‐B Leader With BK Polyomavirus and Cytomegalovirus Infections in Kidney Allograft Recipients

Year: 2026
Type: article
Study design: Observational Study
Abstract: Natural killer (NK) cell education and function depend on HLA-E expression, influenced by the dimorphic HLA-B leader peptide (-21M vs. -21T). NK cells help control BK polyomavirus (BKPyV) and cytomegalovirus (CMV) after kidney transplantation, but the HLA-B leader's role is unclear. We retrospectively studied 700 kidney transplants with high-resolution recipient/donor HLA typing, determining the recipient's HLA-B leader genotype (MM 6%, MT 39%, TT 55%) and recipient/donor constellation (345/700 [49%] matched, 355/700 [51%] mismatched). Associations with 1-year occurrence and severity of BKPyV (decoy cell shedding, BKPyV-DNAemia, presumptive BKPyV-associated nephropathy [BKPyVAN]) and CMV (DNAemia, disease) were assessed with univariate analyses and multivariable Cox and logistic regression. One-year incidence of decoy cell shedding was similar across genotypes (MM 28.3%, MT 29.0%, TT 33.5%; p = 0.37) and between matched and mismatched recipients (31.0% vs. 31.8%; p = 0.79); BKPyV-DNAemia incidence likewise did not differ by genotype (MM 19.6%, MT 16.5%, TT 18.9%; p = 0.73) or constellation (15.9% vs. 20.0%; p = 0.16). In multivariable models, neither genotype nor constellation was associated with decoy cell shedding, BKPyV-DNAemia, or development of presumptive BKPyVAN. CMV-DNAemia incidence also did not differ by genotype (MM 19.6%, MT 30.9%, TT 28.8%; p = 0.35) or constellation (27.0% vs. 31.0%; p = 0.25). In multivariable models, neither genotype nor constellation was associated with CMV-DNAemia or development of CMV disease. In conclusion, the HLA-B leader is neither associated with the occurrence nor the severity of BKPyV and CMV infections within the first year posttransplant in kidney allograft recipients. This argues against using HLA-B leader information to guide BKPyV or CMV screening strategies.
Source: HLA
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,780
OpenAlex ID: W7225424510
FWCI:
Cites: 29
Cited by:
Related to: 10